MOSCOW (Reuters) - Russia expects several European Union countries to approve the use of its Sputnik V vaccine this month and Moscow could provide vaccines for 50 million Europeans starting from June if the shot wins EU-wide approval, Russia’s RDIF fund said on Thursday.
Kirill Dmitriev, CEO of the RDIF sovereign wealth fund that is promoting Sputnik V internationally, was speaking after the European Medicines Agency said it had begun a rolling review of Sputnik V.
Dmitriev told Reuters that the shot could act as a bridge between Russia and Europe, and that its potential roll-out should not get bogged down in politics.
Reporting by Andrew Osborn; writing by Tom Balmforth; editing by Andrew Osborn
Our Standards: The Thomson Reuters Trust Principles.